“Enbrel had reached the end of its patent life and its profits were dwindling, meaning it may have made little business sense to invest in the trial, according to the Post. “
this is totally ridiculous: any drug company worth its salt will give its left nut to obtain a new patent for a new use for an old drug that has an expiring patent for an old use ...
They are not going to be given a new patent for a new use. That's not how it works.By the time any clinical trial might be completed, the patent for this would have run out, which would mean it would be hard to recover the costs of the clinical trials. This was a reasonable economic decision, but they should have published the results of their analysis of insurance claims.